BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Necitumumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Necitumumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04285671-2026@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:Necitumumab: Phase 1/2 readout est. (NCT04285671)
DESCRIPTION:Necitumumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: N
 ecitumumab and Trastuzumab in Combination With Osimertinib for the Treatme
 nt of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV 
 Non-small Cell Lung Cancer\nEstimated primary completion: 2 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/necitumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04285671
URL:https://assetmemo.bio/drug/necitumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496663-2026@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Necitumumab: Phase 1 readout est. (NCT02496663)
DESCRIPTION:Necitumumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Osi
 mertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or
  Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EG
 FR Tyrosine Kinase Inhibitor\nEstimated primary completion: 30 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/necitumumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02496663
URL:https://assetmemo.bio/drug/necitumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
